US President Donald Trump has announced deals that aim to lower the cost of popular weight loss drugs, as phramaceutical prices take centre stage in his administration's messaging around affordability ...

On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions ...

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Understand the challenges and solutions around pharmacy benefits as costs rise and new drugs enter the market.

Five top-selling drugs, in some cases, are costing Americans thousands in out of pocket expenses weekly and monthly. Here's ...

UnitedHealth Group remains a top pick with strong EPS growth, AI-driven savings, and steady revenues. Click here to read an ...

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...

Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying ...

“The actions outlined today will better position us to drive meaningful earnings growth and further strengthen the company to ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid guidance for 2025.